Multi-target novel neuroprotective compound ITH33/IQM9.21 inhibits calcium entry, calcium signals and exocytosis

Cell Calcium

Volumn 50, Issue 4, 2011, Pages 359-369

  Maroto, Marcos ^a,b   de Diego, Antonio M G ^a,b   Albiñana, Elisa ^a,b   Fernandez Morales, José C ^a,b   Caricati Neto, Afonso ^a,e   Jurkiewicz, Aron ^a,e   Yáñez, Matilde ^a,f   Rodriguez Franco, María Isabel ^d   Conde, Santiago ^d   Arce, Mariana P ^d   Hernández Guijo, Jesús M ^a,b,c   García, Antonio G ^a,b,c  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Calcium channels; Calcium signalling; Calcium dependent potassium channels; Exocytosis; ITH33 IQM9.21

Indexed keywords

CALCIUM ION; FURA 2; GLUTAMIC ACID DERIVATIVE; N BENZOYL GLUTAMIC ACID[AMINO (1 BENZYLPIPERIDIN 4 YL)ETHYL]HEXYL OXALIC ACID; POTASSIUM ION; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM SIGNALING; CALCIUM TRANSPORT; CATECHOLAMINE RELEASE; CELL MEMBRANE DEPOLARIZATION; CELL POPULATION; CHROMAFFIN CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG STRUCTURE; EXOCYTOSIS; INHIBITION KINETICS; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROPROTECTION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; SODIUM CURRENT;

BOVINAE;

EID: 80053324356     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2011.06.006     Document Type: Article

References (52)

1. Katz B., Miledi R. The effect of calcium on acetylcholine release from motor nerve terminals. Proc. R. Soc. Lond. B: Biol. Sci. 1965, 161:496-503.
2. Ghosh A., Ginty D.D., Bading H., Greenberg M.E. Calcium regulation of gene expression in neuronal cells. J. Neurobiol. 1994, 25:294-303.
3. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1:11-21.
4. Berridge M.J., Bootman M.D., Lipp P. Calcium-a life and death signal. Nature 1998, 395:645-648.
5. Fleckenstein A., Frey M., Fleckenstein-Grun G. Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur. Heart J. 1983, 4(Suppl. H):43-50.
6. Leonard J.P., Salpeter M.M. Agonist-induced myopathy at the neuromuscular junction is mediated by calcium. J. Cell Biol. 1979, 82:811-819.
7. Schanne F.A., Kane A.B., Young E.E., Farber J.L. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.
8. Trump B.F., Berezesky I.K. Calcium-mediated cell injury and cell death. FASEB J. 1995, 9:219-228.
9. 2+ determine nerve growth factor dependence of sympathetic ganglion cells. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:6421-6425.
10. Franklin J.L., Johnson E.M. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 1992, 15:501-508.
11. Choi D.W. Ischemia-induced neuronal apoptosis. Curr. Opin. Neurobiol. 1996, 6:667-672.
12. Mergenthaler P., Dirnagl U., Meisel A. Pathophysiology of stroke: lessons from animal models. Metab. Brain Dis. 2004, 19:151-167.
13. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22:391-397.
14. Broughton B.R., Reutens D.C., Sobey C.G. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-e339.
15. Shuaib A., Hussain M.S. The past and future of neuroprotection in cerebral ischaemic stroke. Eur. Neurol. 2008, 59:4-14.
16. Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005, 26:27-35.
17. Bolognesi M.L., Matera R., Minarini A., Rosini M., Melchiorre C. Alzheimer's disease: new approaches to drug discovery. Curr. Opin. Chem. Biol. 2009, 13:303-308.
18. Buccafusco J.J., Letchworth S.R., Bencherif M., Lippiello P.M. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol. Sci. 2005, 26:352-360.
19. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51:347-372.
20. R. León, A.G. García, J. Marco-Contelles, Recent advances in the multi-target directed ligands approach for the treatment of cerebrovascular and Alzheimer's diseases, Med. Res. Rev., in press, doi:10.1002/med.20248.
21. Marco-Contelles J., Leon R., de los Rios C., Samadi A., Bartolini M., Andrisano V., Huertas O., Barril X., Luque F.J., Rodriguez-Franco M.I., Lopez B., Lopez M.G., Garcia A.G., Carreiras Mdo C., Villarroya M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem. 2009, 52:2724-2732.
22. Fernandez-Bachiller M.I., Perez C., Campillo N.E., Paez J.A., Gonzalez-Munoz G.C., Usan P., Garcia-Palomero E., Lopez M.G., Villarroya M., Garcia A.G., Martinez A., Rodriguez-Franco M.I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009, 4:828-841.
23. de Los Rios C., Egea J., Marco-Contelles J., Leon R., Samadi A., Iriepa I., Moraleda I., Galvez E., Garcia A.G., Lopez M.G., Villarroya M., Romero A. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J. Med. Chem. 2010, 53:5129-5143.
24. Arce M.P., Rodriguez-Franco M.I., Gonzalez-Munoz G.C., Perez C., Lopez B., Villarroya M., Lopez M.G., Garcia A.G., Conde S. Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J. Med. Chem. 2009, 52:7249-7257.
25. Garcia A.G., Garcia-De-Diego A.M., Gandia L., Borges R., Garcia-Sancho J. Calcium signaling and exocytosis in adrenal chromaffin cells. Physiol. Rev. 2006, 86:1093-1131.
26. Livett B.G. Adrenal medullary chromaffin cells in vitro. Physiol. Rev. 1984, 64:1103-1161.
27. Moro M.A., Lopez M.G., Gandia L., Michelena P., Garcia A.G. Separation and culture of living adrenaline- and noradrenaline-containing cells from bovine adrenal medullae. Anal. Biochem. 1990, 185:243-248.
28. Wightman R.M., Jankowski J.A., Kennedy R.T., Kawagoe K.T., Schroeder T.J., Leszczyszyn D.J., Near J.A., Diliberto E.J., Viveros O.H. Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10754-10758.
29. Machado D.J., Montesinos M.S., Borges R. Good practices in single-cell amperometry. Methods Mol. Biol. 2008, 440:297-313.
30. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981, 391:85-100.
31. 2+ loads from rat adrenal chromaffin cells. Neuron 1996, 16:219-228.
32. Fernandez-Morales J.C., Yanez M., Orallo F., Cortes L., Gonzalez J.C., Hernandez-Guijo J.M., Garcia A.G., de Diego A.M. Blockade by nanomolar resveratrol of quantal catecholamine release in chromaffin cells. Mol. Pharmacol. 2010, 78(4):734-744.
33. Fernandez-Morales J.C., Cortes-Gil L., Garcia A.G., de Diego A.M. Differences in the quantal release of catecholamines in chromaffin cells of rat embryos and their mothers. Am. J. Physiol. Cell Physiol. 2009, 297:C407-C418.
34. Cuchillo-Ibanez I., Olivares R., Aldea M., Villarroya M., Arroyo G., Fuentealba J., Garcia A.G., Albillos A. Acetylcholine and potassium elicit different patterns of exocytosis in chromaffin cells when the intracellular calcium handling is disturbed. Pflugers Arch. 2002, 444:133-142.
35. Marty A. Ca-dependent K channels with large unitary conductance in chromaffin cell membranes. Nature 1981, 291:497-500.
36. + channels in bovine chromaffin cells. Pflugers Arch. 1993, 423:97-103.
37. Prakriya M., Lingle C.J. Activation of BK channels in rat chromaffin cells requires summation of Ca(2+) influx from multiple Ca(2+) channels. J. Neurophysiol. 2000, 84:1123-1135.
38. Montiel C., Lopez M.G., Sanchez-Garcia P., Maroto R., Zapater P., Garcia A.G. Contribution of SK and BK channels in the control of catecholamine release by electrical stimulation of the cat adrenal gland. J. Physiol. 1995, 486(Pt 2):427-437.
39. 2+ and membrane capacitance upon steady or action potential depolarizing stimulation of bovine chromaffin cells. Acta Physiol. (Oxf.) 2008, 194:97-109.
40. 2+ transients that modulate secretion. Nat. Cell Biol. 2000, 2:57-61.
41. 2+ revealed by specifically targeted recombinant aequorin. Nature 1992, 358:325-327.
42. Garcez-Do-Carmo L., Albillos A., Artalejo A.R., de la Fuente M.T., Lopez M.G., Gandia L., Michelena P., Garcia A.G. R56865 inhibits catecholamine release from bovine chromaffin cells by blocking calcium channels. Br. J. Pharmacol. 1993, 110:1149-1155.
43. Hernandez-Guijo J.M., Gandia L., de Pascual R., Garcia A.G. Differential effects of the neuroprotectant lubeluzole on bovine and mouse chromaffin cell calcium channel subtypes. Br. J. Pharmacol. 1997, 122:275-285.
44. 2+ channels of chromaffin cells. Eur. J. Pharmacol. 1997, 320:249-257.
45. 2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine. Mol. Pharmacol. 1989, 36:525-531.
46. Ashton D., Willems R., Wynants J., Van Reempts J., Marrannes R., Clincke G. Altered Na(+)-channel function as an in vitro model of the ischemic penumbra: action of lubeluzole and other neuroprotective drugs. Brain Res. 1997, 745:210-221.
47. Marcantoni A., Vandael D.H., Mahapatra S., Carabelli V., Sinnegger-Brauns M.J., Striessnig J., Carbone E. Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J. Neurosci. 2010, 30:491-504.
48. Barrett E.F., Barret J.N. Separation of two voltage-sensitive potassium currents, and demonstration of a tetrodotoxin-resistant calcium current in frog motoneurones. J. Physiol. 1976, 255:737-774.
49. Roda J.M., Carceller F., Diez-Tejedor E., Avendano C. Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 1995, 26:1888-1892.
50. Sobrado M., Lopez M.G., Carceller F., Garcia A.G., Roda J.M. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 2003, 118:107-113.
51. Horn J., de Haan R.J., Vermeulen M., Luiten P.G., Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 2001, 32:2433-2438.
52. Saver J.L., Albers G.W., Dunn B., Johnston K.C., Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009, 40:2594-2600.